Bacterial Chassis Genome Integration Patents: Leaders & Trends 2026
Bacterial Chassis Genome Integration Patents: Who Holds the Ground
23.0% concentration at the top. The five leading assignees hold 935 of the 4,065 records in scope, but the other 77% is spread across a long tail of single- and few-filing entrants. Publications rose from 82 in 2017 to a peak of 127 in 2020, then declined; the corpus shows a -62% move from 117 records in 2021 to 44 in 2024, the last year treated as complete given the ~18-month publication lag.
- 1NOVOZYMES AS9.4%
- 2CORIXA CORP3.7%
- 3THE SCRIPPS RES INST3.7%
- 4NOVOZYMES INC3.3%
- 5MONSANTO TECHNOLOGY LLC2.9%
See the full bacterial chassis genome integration analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on this landscape
Who are the leading patent holders in bacterial chassis genome integration?
The ranking covers 100 assignees scored against 4,065 records, with the leading company holding 383 records and a clear gap down to fifth place at 117. The top five combined account for 23.0% of all records in scope, meaning the field has a recognisable leader but is far from a closed field — the remaining 77% is spread across many smaller filers. Anyone doing freedom-to-operate work should check both the leader’s core claims and the long tail, since single-filing entities are easy to overlook.
Is patent filing in this area growing or slowing?
Filings peaked at 127 records in 2020, and the corpus shows a documented -62% change from 117 records in 2021 to 44 in 2024, the last year treated as complete. Because publication typically lags filing by around 18 months, the 2025–2026 figures in the dataset are still filling in and should not be read as confirmation of a continued decline. The honest read is a real post-2020 cooling with an open question about where it settles.
What patent classes cover bacterial chassis genome integration?
The core class is C12N, covering microorganisms and genetic engineering, present in 93.0% of the 4,065 records. Beneath that, C07K (peptides and proteins) appears in 48.4% of records, C12P (fermentation and enzymatic synthesis) in 42.3%, and C12Q (enzyme/DNA-based measuring) in 38.4%. Because a single record can carry several IPC classes, these shares add up to more than 100% — most filings combine a chassis-engineering claim with a product, assay, or therapeutic claim rather than filing on the host organism alone.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on Bacterial Chassis Genome Integration covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.